Search company, investor...
PharmaSwiss company logo


Founded Year



Growth Equity | Alive

Total Raised




Last Raised

$45.8M | 15 yrs ago

About PharmaSwiss

PharmaSwiss SA is a medium sized pharmaceutical company. Established in Switzerland in 2000, PharmaSwiss handles an entire piece of business that is logistically and financially impractical for companies whose strategic focus is elsewhere in the world. We form exclusive, long-term partnerships with research-based pharmaceutical MNCs and Biotechs, as well as hospitals, clinics, doctors and pharmacies, providing integrated services in each country including: Pre-registration named patient sales Registration of medicines with local authorities Pharmacovigilance and Ethical Marketing Compliance Medical education, including investigator meetings and symposia Sales and promotion

Headquarters Location



Missing: PharmaSwiss's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PharmaSwiss's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest PharmaSwiss News

Cystic Fibrosis Drugs Market – Notable Developments, Future Trends & Future Applications 2025

Jan 23, 2020

Cystic Fibrosis Drugs Market report enhanced on worldwide competition by topmost prime manufactures (Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Vertex Pharmaceuticals, Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics, Boehringer Ingelheim, Chiesi Farmaceutici, Corbus Pharmaceuticals, Genzyme, Insmed, Johnson & Johnson, Merck Sharp & Dohme, Neovii Biotech, Novo Nordisk, PharmaSwiss, Pharmaxis, Proteostasis Therapeutics, PTC Therapeutics, United Medical, Venus Remedies) which providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. This Cystic Fibrosis Drugs market research report also analyzes adoption trends, key challenges, future growth potentials, key drivers, competitive outlook, restraints, opportunities, market ecosystem, and value chain analysis. Cystic Fibrosis Drugs industry research presents a detailed analysis, market sizing, and forecasting (6 Year 2019-2025) for the emerging segment within the Cystic Fibrosis Drugs market. The report is thoroughly segmented by product type, application, vertical, and region. Get Free Sample PDF (including full TOC, Tables and Figures) of Cystic Fibrosis Drugs [email protected]    Cystic Fibrosis Drugs Market Competition by Manufacturers (2019-2025) Cystic Fibrosis Drugs Market Share of Top 3 and Top 5 Manufacturers, Revenue and Share by Manufacturers, Manufacturers Manufacturing Base Distribution, Sales Area, Market Competitive Situation and Trends,Cystic Fibrosis Drugs Market by Capacity, Production and Share by Manufacturers. Scope of Cystic Fibrosis Drugs Market:  The Cystic Fibrosis Drugs market report analyzes the opportunities in the global market, analyzing the data on a historical basis, estimated data for 2018, and forecasted data till the year 2025. Market analysis includes data in terms of both, value (US$) and volume (MT). The market outlook of the Cystic Fibrosis Drugs market report covers feed industry overview, global industry outlook, macroeconomic outlook, and forecasted factors. The market dynamics section includes key drivers, trends, and restraints prohibiting the growth of the Cystic Fibrosis Drugs market, value chain analysis, and others On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, Cystic Fibrosis Drugs market share and growth rate of Cystic Fibrosis Drugs for each application, including- Hospitals Other On the basis of product, this report displays the sales volume, revenue (Million USD), product price, Cystic Fibrosis Drugs market share and growth rate of each type, primarily split into- Oral Injection Key Questions Answered in the Report: What are the Competition Developments and Trendsin the Cystic Fibrosis Drugs market? What are the Key Challenges, Opportunities, and Improvementsfaced by market players in the global Cystic Fibrosis Drugs market? What are the underlying Macro-Economic and Industry Factorsimpacting the growth of the Cystic Fibrosis Drugs market? How is the Cystic Fibrosis Drugs market expected to Grow In Terms Of Valueduring the study period? Geographically, the report includes the research on production, consumption, revenue, Cystic Fibrosis Drugs market share and growth rate, and forecast (2019-2025) of the following regions: United States, China, Japan, India, Other Regions Europe (Germany, UK, France, Italy, Spain, Russia, Poland) Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam) Central and South America (Brazil, Mexico, Colombia) Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria) Contact:

PharmaSwiss Frequently Asked Questions (FAQ)

  • When was PharmaSwiss founded?

    PharmaSwiss was founded in 2000.

  • What is PharmaSwiss's latest funding round?

    PharmaSwiss's latest funding round is Growth Equity.

  • How much did PharmaSwiss raise?

    PharmaSwiss raised a total of $45.8M.

  • Who are the investors of PharmaSwiss?

    Investors of PharmaSwiss include Enterprise Investors and HBM Healthcare Investments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.